1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Europe Neoantigens Market – By Treatment

1.3.2        Europe Neoantigens Market – By Therapeutic Specialty

1.3.3        Europe Neoantigens Market– By Country

2.           Europe Neoantigens Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Europe Neoantigens Market– Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Europe PEST Analysis

4.3         Expert Opinion

5.           Neoantigens Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Evolution in Neoantigen Vaccines Against Cancer

5.1.2        Rising Prevalence of Cancer

5.2         Market Restraints

5.2.1        Possible Side Effects Associated with Neoantigen Vaccines

5.3         Market Opportunities

5.3.1        Application of Next-generation Sequencing for Neoantigen Identification

5.4         Future Trends

5.4.1        Use of AI in Neoantigen Vaccine Development

5.5         Impact Analysis

6.           Neoantigens Market – Europe Analysis

6.1         Europe Neoantigens Market Revenue Forecast and Analysis

7.           Europe Neoantigens Market Analysis – By Treatment

7.1         Overview

7.2         Europe Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

7.3         Combination Therapy

7.3.1        Overview

7.3.2        Combination Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

7.4         Mono Therapy

7.4.1        Overview

7.4.2        Mono Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.           Europe Neoantigens Market Analysis – By Therapeutic Specialty

8.1         Overview

8.2         Europe Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

8.3         Gastrointestinal Cancer

8.3.1        Overview

8.3.2        Gastrointestinal Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.4         Lung Cancer

8.4.1        Overview

8.4.2        Lung Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.5         Solid Tumors

8.5.1        Overview

8.5.2        Solid Tumors: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.6         Urinary System Cancers

8.6.1        Overview

8.6.2        Urinary System Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.7         Melanoma

8.7.1        Overview

8.7.2        Melanoma: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.8         Head and Neck Cancers

8.8.1        Overview

8.8.2        Head and Neck Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.9         Others

8.9.1        Overview

8.9.2        Others: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

9.           Europe Neoantigens Market – Country Analysis

9.1         Europe: Neoantigens Market

9.1.1        Overview

9.1.2        Europe: Neoantigens Market, by Country, 2023 & 2028(%)

9.1.3        Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.1          Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.2          Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.3          Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.4        France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.1          France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.2          France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.3          France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.5        UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.1          UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.2          UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.3          UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.6        Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.1          Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.2          Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.3          Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.7        Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.1          Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.2          Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.3          Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.8        Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.1          Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.2          Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.3          Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

10.        Impact Of COVID-19 Pandemic on Europe Neoantigens Market

10.1      Europe: Impact Assessment of COVID-19 Pandemic

11.        Neoantigens Market–Industry Landscape

12.        Company Profiles

12.1      Achilles Therapeutics plc

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Frame Cancer Therapeutics

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      Genocea

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      Immunicum AB

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      Medigene AG

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      Moderna, Inc.

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

13.        Appendix

13.1      About the Insight Partners

13.2      Glossary of Terms

Table 1.             New Cancer Cases Registered Worldwide, 2020

Table 2.             Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

Table 3.             Incidence, Mortality and Prevalence by cancer site, 2020, Germany

Table 4.             Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 5.             Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 6.             Incidence, Mortality and Prevalence by cancer site, 2020, France

Table 7.             France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 8.             France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 9.             UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 10.          UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

Table 11.          Incidence, Mortality and Prevalence by cancer site, 2020, Italy

Table 12.          Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 13.          Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 14.          Incidence, Mortality and Prevalence by cancer site, 2020, Spain

Table 15.          Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 16.          Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 17.          Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 18.          Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028  (USD Thousand)

Table 19.          Market Developments Done By Companies

Table 20.          Glossary of Terms, Neoantigens Market

Figure 1.           Europe Neoantigens Market Segmentation

Figure 2.           Europe Neoantigens Segmentation, By Country

Figure 3.           Europe Neoantigens Market Overview

Figure 4.           Combination Therapy Segment Holds Largest Share of Europe Neoantigens Market

Figure 5.           Germany to Show Remarkable Growth During Forecast Period

Figure 6.           Europe: PEST Analysis

Figure 7.           Expert Opinion

Figure 8.           Europe Neoantigens Market Impact Analysis of Drivers and Restraints

Figure 9.           Europe Neoantigens Market – Revenue Forecast and Analysis – 2023- 2028

Figure 10.        Europe Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

Figure 11.        Combination Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 12.        Mono Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 13.        Europe Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

Figure 14.        Gastrointestinal Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 15.        Lung Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 16.        Solid Tumors: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 17.        Urinary System Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 18.        Melanoma: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 19.        Head and Neck Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 20.        Others: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 21.        Europe: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 22.        Europe: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 23.        Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 24.        France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 25.        UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 26.        Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 27.        Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 28.        Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 29.        Impact of COVID-19 Pandemic in European Country Markets